All-trans Retinoic Acid (ATRA) in the Treatment of Recurrent/Metastatic Adenoid Cystic Carcinoma of the Head and Neck

STATUS

Recruiting
participants needed

30
sponsor

Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University

Send

Updated on 19 February 2024

See if I qualify

blood transfusion

ct scan

measurable disease

metastasis

liver metastasis

carcinoma

spiral computed tomography

blood test

liver metastases

tretinoin

metastatic adenoid cystic carcinoma

Summary

This is a prospective, open-label, randomized controlled clinical intervention study to evaluate the efficacy and safety of all-trans retinoic acid (ATRA) in treating patients with recurrent metastatic adenoid cystic carcinoma of the head and neck.

Details

Condition	Adenoid Cystic Carcinoma of the Head and Neck
Age	18years - 100years
Treatment	Chemotherapy, All-trans Retinoic Acid, VEGFR inhibitor
Clinical Study Identifier	NCT04433169
Sponsor	Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University
Last Modified on	19 February 2024

How understandable was the trial content above?

Hard to understand

Easy to understand

Eligibility		Yes	No	Not Sure
Inclusion Criteria
	Age 18 years, male or female; 2. ECOG PS (performance status) score: 0-1; 3. Pathologically or histologically confirmed advanced, recurrent/metastatic ACC, with measurable disease (10 mm by spiral CT scan, meeting RECIST 1.1 criteria); 4. Patients with therapeutic indications; 5. Main organ functions normal, i.e., meeting the criteria
	below
	Criteria for routine blood test: (no blood transfusion within 14 days)
	HB 90 g/L
	WBC 3.5 109/L and < 10 109/L
	ANC 1.5 109/L
	PLT 80 109/L
	Criteria for biochemical tests
	BIL < 1.25 upper limit of normal (ULN)
	ALT and AST < 2.5 ULN; in the presence of metastases to liver, ALT and AST < 5 ULN
	Serum Cr 1 ULN, endogenous creatinine clearance > 50 mL/min (Cockcroft-Gault equation); 5. Subjects who volunteer to participate in this study, sign the informed consent, have good compliance and cooperate in follow-up; 6. Patients who, in the doctor's opinion, can benefit from the treatment
Exclusion Criteria
	Previous or existing concomitant malignancies except cured skin basal cell carcinoma or cervical carcinoma in situ
	Coagulation abnormal (INR>1.5, APTT>1.5ULN), history of gastrointestinal hemorrhage in the past 6 months or bleeding tendency [e.g., presence of active ulcer focus in the stomach, stool occult blood (++), melena and/or hematemesis, hemoptysis in the past 3 months]
	Confirmed hypersensitivity to ATRA
	Grade I and above coronary artery diseases, arrhythmias [including QTc prolongation (males: > 450 ms, females: > 470 ms)] and cardiac dysfunction
	Presence of multiple factors affecting oral administration (e.g. dysphagia, nausea, vomiting, chronic diarrhea and intestinal obstruction, etc.)
	Pregnant or lactating women
	History of psychotropic abuse with abstinence failure, or existing mental disorder
	Participation in other drug clinical trials within 4 weeks
	Other concomitant diseases which seriously jeopardize the patient's safety or prevent the patient from completing the study, as judged by the investigator

How to participate?

Step 1 Connect with a study center

Select a site
Send a message

You have contacted , on

Your message has been sent to the study team at ,

A copy of the message has been sent to your email

What happens next?

You can expect the study team to contact you via email or phone in the next few days.
Sign up as volunteer to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Primary Contact

I am at least 18 years old.

By sending a message, I agree to share my information with the study team for the selected site and consent to receive emails and text messages for trial updates, notifications, and related communication. TrialX values your privacy; your information will be handled in accordance with our Privacy Policy

Step 2 Get screened

Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

Step 3 Enroll in the clinical study

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Step 4 Get your study results

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider

Browse trials for

spiral computed tomography

blood test

liver metastases

tretinoin

metastatic adenoid cystic carcinoma

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Study Definition

Wikipedia

All-trans Retinoic Acid (ATRA) in the Treatment of Recurrent/Metastatic Adenoid Cystic Carcinoma of the Head and Neck